SGLT-2 inhibitors like sotagliflozin are antihyperglycemic agents approved in the US for use in patients with type 2 diabetes. However, sotagliflozin is also approved for type 1 diabetes in Europe, and studies have shown that using sotagliflozin along with insulin has benefits in patients with type 1 diabetes. Read more